News

CE-IVD Approval Marks SkylineDx’s European Commercialization of its MMprofiler technology Rotterdam, the Netherlands and Laguna Hills, CA, November 25, 2015 – SkylineDx, today announced they have received CE-IVD registration from the European Competent...

Article in Blood shows the reliability of SKY92 genetic subtyping signature for prediction of disease progress for multiple myeloma (bone marrow cancer) patients Rotterdam, the Netherlands, 8 September 2015 – Researchers at the...

Key additions to the management team as SkylineDx accelerates its development of gene signature-based diagnostics and prepares for the launch of its first product Rotterdam, The Netherlands, 19 August 2015 – SkylineDx, a...

Test of Dutch-based SkylineDx gives patients better insight in their chances and enables clinicians to adjust their treatment Rotterdam, 2 July 2015 – SkylineDx, an innovative biotechnology company specialising in the development and...

Boston (U.S.) – Rotterdam (NL), June 8, 2015. On the 13th of June SkylineDx will present an abstract detailing the comparison of SKY92 GEP, IFISH AND ISS for risk identification in Multiple...